Cepheid is now an indirect wholly owned subsidiary of Danaher, and the firm's stock will no longer be traded on the Nasdaq.
The firm, which is in the process of being acquired by Danaher, reported strong revenue growth for both its consumables and systems.
The GenomeWeb Index fell nearly 9 percent in October, doubling back on September's 5 percent gain and underperforming the Dow and the Nasdaq.
The test is the first in a proposed line of assays that will run on the GeneXpress platform with run times of around 30 minutes.
The company said it ultimately plans to use the liquidity from the credit facility to fund a portion of its pending $4 billion acquisition of Cepheid.
The $4 billion acquisition is now cleared in the US, Germany, Austria, and South Africa.
The company's revenues were in line with analyst expectations, while its adjusted earnings per share of $.87 beat expectations.
The Xpert Bladder Cancer Monitor test for the GeneXpert system has a high negative predictive value and provides results non-invasively in about 90 minutes.
The GenomeWeb Index gained more than 5 percent in September, after falling more than 2 percent in August, and outperformed the Nasdaq Biotechnology Index.
Danaher expects shareholders will see returns from the acquisition in the fifth year, as post-acquisition cost savings and revenues kick in.
Mainichi reports that 43 percent of Japanese individuals said they did not want to eat agricultural products that had been modified using gene-editing tools.
Two US Department of Agriculture research departments are moving to the Kansas City area, according to the Washington Post.
Slate's Jane Hu compares some at-home genetic tests to astrology.
In PLOS this week: analysis of polygenic risk scores for skin cancer, chronic pain GWAS, and more.